FDA clears C2N Diagnostics’ early Alzheimer’s assessment test
C2N’s Alzheimer’s test is the first to be FDA-cleared for use in patients as young as 40 who present with cognitive impairment symptoms.
C2N’s Alzheimer’s test is the first to be FDA-cleared for use in patients as young as 40 who present with cognitive impairment symptoms.
With regulatory conditions tightening around climate impact and environmental persistence of medical propellants, HFA-152a is a practical route to maintain clinical performance, patient outcomes and supply continuity of inhalers. However,...
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
UK government champions healthtech through new NHS access programme
Intuitive Surgical expands platforms despite market headwind
The increased importance of safety for wearable devices
What does the EU Data Act mean for businesses?